Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02680782 · ClinicalTrials.gov registry record · Phase 1
A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers
A Phase 1 study, sponsored by X4 Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02680782 is a Phase 1 study that was terminated before completion, run by X4 Pharmaceuticals. The registered enrollment target is 15 participants.
The verdict
NCT02680782, a Phase 1 study, was terminated before completion, sponsored by X4 Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability and pharmacokinetics of X4P-001 administered as 200 mg twice daily compared with 400 mg once daily. This study will also assess the pharmacodynamic effects of X4P-001 administered as 200 mg twice daily compared with 400 mg once daily on levels of circulating white blood cells (total and by cell type).
Interventions
- DRUG X4P-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2016-01-12 |
| Est. Completion | 2016-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02680782
The ClinicalTrials.gov registry entry for NCT02680782 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is X4 Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which X4P-001 is the first listed.
NCT02680782 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02680782 about?
NCT02680782 is a clinical study titled "A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers". This study will evaluate the safety, tolerability and pharmacokinetics of X4P-001 administered as 200 mg twice daily compared with 400 mg once daily. This study will also assess the pharmacodynamic effects of X4P-001 administered as 200 mg twice daily compared with 400 mg once daily on levels of ci...
What is the current status of trial NCT02680782?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2016-01-12. Estimated completion is 2016-02-28.
What interventions are being tested in trial NCT02680782?
The interventions under investigation include: X4P-001 (DRUG).
Who is sponsoring clinical trial NCT02680782?
This trial is sponsored by X4 Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.